“Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis” (2009) Reumatismo, 61(3), pp. 182–186. doi:10.4081/reumatismo.2009.182.